Fineline Cube

China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026

China’s National Health Commission (NHC) announced that chikungunya fever and severe fever with thrombocytopenia syndrome...

Company Drug

Gan & Lee’s Bonfaglutide Wins NMPA Approval for OSA Study – Biweekly GLP‑1 Expands to Sleep Apnea Indication

Fineline Cube Mar 25, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced NMPA clinical trial approval to initiate a study...

Company Drug

Clover Bio Reports Positive SCB‑1019 Phase I Data – RSV PreF Vaccine Demonstrates Superior Booster Response vs. GSK’s Arexvy

Fineline Cube Mar 25, 2026

Clover Biopharmaceuticals Ltd. (HKG: 2197) announced additional positive Phase I data from its US clinical...

Company

Merck KGaA Inaugurates China R&D Center – Beijing BioPark Hub Targets First‑Tier Global Drug Launch Status

Fineline Cube Mar 25, 2026

Merck KGaA (ETR: MRK) announced the inauguration of its China R&D Center at the BioPark...

Company

Atom Therapeutics Files Hong Kong IPO – URAT1 Inhibitor ABP-671 Targets First‑Line Gout Treatment Market

Fineline Cube Mar 25, 2026

Atom Therapeutics Co., Ltd. has submitted an initial public offering (IPO) filing to the Hong...

Company Deals

Asieris Pharma Partners with SPH Keyuan to Commercialize Cevira – World’s First Non‑Surgical Cervical Precancer Treatment Launches in China

Fineline Cube Mar 25, 2026

Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176), a urogenital cancer specialist, has entered into a...

Company Drug

Henlius Biotech Wins Health Canada Approval for Denosumab Biosimilars – Bildyos and Tuzemty Expand Organon Partnership to Canada

Fineline Cube Mar 25, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced marketing approval from Health Canada for Bildyos (denosumab...

Company Drug

Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation – First‑in‑Class Claudin18.2/CD3 Bispecific Enters Phase III for Pancreatic Cancer

Fineline Cube Mar 25, 2026

Qilu Pharmaceutical Co., Ltd. announced that QLS31905, its Claudin18.2/CD3 bispecific T‑cell engager (BsAb), has received...

Company

WuXi Biologics Reports 2025 Revenue Growth 16.7% – Net Profit Surges 46.3% on Record 209 New Projects

Fineline Cube Mar 25, 2026

WuXi Biologics Co., Ltd. (HKG: 2269) announced strong 2025 annual results, with total revenue rising...

Company Drug

Bayer/Regeneron’s Eylea HD Wins Japan Approval for RVO – Third Indication Nod with Extended Dosing Demonstrates 3 Fewer Injections

Fineline Cube Mar 25, 2026

Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Eylea HD (aflibercept) injection 8...

Company Deals

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise

Fineline Cube Mar 25, 2026

Sciwind Biosciences Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, seeking...

Company Drug

Sanofi’s Dupixent Wins Japan Approval for Bullous Pemphigoid – Seventh Indication Expands IL‑4/IL‑13 Franchise

Fineline Cube Mar 25, 2026

Sanofi S.A. (NASDAQ: SNY) announced that Dupixent (dupilumab) has received marketing approval from Japan’s Ministry...

Company Drug

Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases

Fineline Cube Mar 25, 2026

Fujian Haixi Pharmaceuticals Co., Ltd. (HKG: 2637) announced the initiation of a Phase II clinical...

Company Drug

IASO Bio Wins Japan PMDA Approval for Fucaso CAR‑T – BCMA Therapy Enters Phase III in Relapsed/Refractory Multiple Myeloma

Fineline Cube Mar 25, 2026

IASO Biotherapeutics announced receiving tacit clinical approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)...

Company

Kelun‑Biotech Reports 2025 Revenue RMB 2.06 Billion – Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification

Fineline Cube Mar 25, 2026

Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced annual results for 2025, with full‑year revenue...

Company Drug

Hope Medicine Doses First Patient in HMI-115 Phase III – First-in-Class Non-Hormonal Endometriosis Therapy Advances in China

Fineline Cube Mar 25, 2026

Hope Medicine Inc. announced first patient dosing in a Phase III clinical study evaluating HMI-115,...

Company Drug

Kelun‑Biotech’s SKB103 Wins NMPA Approval – Novel TAA‑PD‑L1 Bispecific ADC Enters Clinical Trials for Advanced Solid Tumors

Fineline Cube Mar 25, 2026

Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its SKB103, a novel TAA‑PD‑L1 bispecific...

Company

Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion

Fineline Cube Mar 24, 2026

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced 2025 annual operating results, demonstrating...

Company Drug

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Fineline Cube Mar 24, 2026

Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study of...

Others

Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal

Fineline Cube Mar 24, 2026

Keymed Biosciences Inc. (HKG: 2162) announced that its NewCo partner Ouro Medicines has entered into...

Fineline Cube

You Missed